Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. - Wikidata - wikimedia - TriplyDB

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment.

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment.

http://www.wikidata.org/entity/Q37404886

about

Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?What evidence is there for a delay in diagnostic coding of RA in UK general practice records? An observational study of free text Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review.Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme Cancer risk in immune-mediated inflammatory diseases (IMID).Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs.Safety of biologic therapy in rheumatoid arthritis.Malignancy as a comorbidity in rheumatic diseases.New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.Overview of safety of non-biologic and biologic DMARDs.Abatacept: a review of its use in the management of rheumatoid arthritis.Update on the use of abatacept for the treatment of rheumatoid arthritis.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Safety of off-label biologicals in systemic lupus erythematosus.Subcutaneous abatacept in rheumatoid arthritis: current update.Safety profile of biological therapies for treating rheumatoid arthritis.Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Abatacept: A Review in Rheumatoid Arthritis.[Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].[Lung cancer and rheumatoid arthritis. An interdisciplinary challenge].[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy.The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.Exploring immune checkpoints as potential therapeutic targets in atherosclerosis.Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.[Lymphoma in rheumatic diseases].Current treatment options for psoriatic arthritis: spotlight on abatacept.Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis

P2860

Q26799036-C12791D9-28A7-4146-B7B6-C4E35B6EC5B0 Q28074148-B93CF7F1-9007-4469-BCC1-C34B6D9083C7 Q28596818-41EA40E3-58FC-457C-9447-3A3089F2FB20 Q35176767-72CEBB13-6A0C-4E38-AF30-1286B18BC9FD Q35208434-BD8BBFDB-6465-47D9-9931-E3B9B4ADC560 Q36513512-1585AF84-AF96-4C82-AF91-701F7DD7E5B7 Q36859619-5FF699E5-342B-4F85-A243-04F560286EA3 Q37153407-69C4EFEC-748A-4264-B18E-8D78CCE01E99 Q37390458-C7FDCD59-49BE-49EC-B072-965F1D6FCFD3 Q37944433-28A8F871-12F3-4B0C-97C1-FBEFE4DDDC55 Q38029322-3BDF8821-0062-4B06-A4A9-867AE51FBA3D Q38057370-79AA379F-6CAE-4696-91A7-4636E2AF32EC Q38065768-9736898F-5471-4322-9EAD-8C3B2A4570AF Q38116472-6A64FBA3-5A5A-482D-83FB-5FB961740830 Q38125240-70F3E7A8-91D9-4F7E-8917-722F3326FBB5 Q38208275-40577F4E-0FDF-4640-BE0A-338EB364FB74 Q38284560-F96F75E9-D454-40F7-B25D-9B2A3ECE6A9B Q38544693-8B48E667-99F0-4272-B2ED-88E7AFC3B283 Q38665700-BAE106FE-1C9B-4EBE-8D4E-AA22BEB5BF04 Q38827889-5A65C11C-1584-4275-90C0-044131BD7A75 Q38837769-27C15682-6655-4D4F-8283-8A5EA895B820 Q39309064-AC075403-E734-4DDB-AD1B-0495693FB9F7 Q39368606-1F57DB82-6A58-47D7-AAD8-687DDBF77A4F Q40826525-62D3FB2F-0E93-4B3B-8801-95A867E60AF2 Q40934508-4FB8D052-567C-4EF7-AB17-334C2CD64BC3 Q41176187-69F55929-F306-4849-A143-53F5DE11002B Q41650730-01728A8A-674F-47CF-B968-10E681826F67 Q42044232-5E7F609B-0536-468C-A407-68B80BF34EB9 Q47159355-86124F78-4BFC-48AE-9B92-33234DE7314C Q47224948-DCB50587-1AD7-4708-BD74-0A6AE93A294D Q47620758-D03D815B-3D47-4868-B5F6-83FACC290D72 Q49518769-F71AD6C7-B6FC-4249-9AF9-FCC227EED1A2 Q50057583-7D71D42F-7814-414C-ACB3-45D4C0561545 Q55318901-1C05B9AE-DF6D-4D26-A087-E5A552CA279D Q57956128-D897003F-39FB-42DD-8033-21D2CDE86850

P2860

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment.

http://www.wikidata.org/entity/Q37404886

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Malignancies in the rheumatoid ...... an epidemiological assessment.

@en

Malignancies in the rheumatoid ...... an epidemiological assessment.

@nl

type

label

Malignancies in the rheumatoid ...... an epidemiological assessment.

@en

Malignancies in the rheumatoid ...... an epidemiological assessment.

@nl

prefLabel

Malignancies in the rheumatoid ...... an epidemiological assessment.

@en

Malignancies in the rheumatoid ...... an epidemiological assessment.

@nl

P1433

Q37404886-257F9B5D-9E6A-4FA4-8D1F-A7443887DCF6

P1476

Q37404886-D496AB9A-C4C8-4331-9F46-584E4E394244

P2093

Q37404886-31883A9D-90F9-4DED-87B6-BAB9A9A78109

Q37404886-55498779-DCD1-449C-B616-0009B8EB2B11

Q37404886-607A0807-2568-49D9-9C06-E2C0DB1524B1

Q37404886-74560F63-53ED-4964-A17A-FEF44354A25C

Q37404886-7D6CD90A-0442-47D6-9275-5786A2BF1FD5

Q37404886-8C20FF34-2C95-44EE-A799-125C84726B66

Q37404886-8C97E553-27E5-4FF6-9DAB-0DA56AFDE803

Q37404886-B3ABE72D-22A7-413C-B7A4-1C906FFF549E

Q37404886-BFBFC5B0-1153-4F06-97D9-B42FCAB4FF72

P2860

Q37404886-201E21C6-20F7-4F56-B0C7-5C2B314A5435

Q37404886-21291DCC-1F29-40B6-8CF0-5C6DDE44F95E

Q37404886-27D9F6A6-FDA2-4422-9F17-1EB578A5D6F9

Q37404886-2BFDD72C-28CD-45D6-8038-C3E081FB9AFC

Q37404886-33DE3F46-0AE5-40E7-A434-18FAC7A3925C

Q37404886-46589E9F-A382-46C6-A5CF-B061A0B794F1

Q37404886-478A3276-AA75-4D24-8874-FDD706D94BA2

Q37404886-4DA961BD-40B6-4A4C-BA0E-0F7A36D2B5BA

Q37404886-526E2FE6-202B-4C02-AC5C-828A19F3F719

Q37404886-55ABCA51-58A8-4A77-8667-B588244E32A3

P304

Q37404886-0F6F41B1-1DFC-4D5F-9815-9167A6C601D4

P31

Q37404886-CBD2E53A-7AEE-4EA3-89C3-0E6C5AC73179

P356

Q37404886-CF7EB2D8-945C-4C0D-B66D-6E6560227947

P407

Q37404886-AC2988FE-165C-40A0-A6C0-4E89A5DFCDD0

P433

Q37404886-E681B7C1-4CCC-428D-9664-5ED0F2ED3CA3

P478

Q37404886-9F8EA464-AB52-4B4E-A132-864B1CA0BE72

P577

Q37404886-98795287-CD44-4BF5-9876-639E473A75EC

P5875

Q37404886-FFF90B94-06C6-481F-8425-E1E2F02050D5

P698

Q37404886-638FEF9C-F9E9-4A6F-B758-BAC2967C008E

P921

Q37404886-6914429E-7F44-4EFF-AAD1-3307E55E9D71

P932

Q37404886-2B34F9A1-D122-4122-9EF9-8FD115DCC0D7

P356

ARD.2008.097527

P1433

Annals of the Rheumatic Diseases

P1476

Malignancies in the rheumatoid ...... an epidemiological assessment.

@en

P2093

A L Smitten

http://www.w3.org/2001/XMLSchema#string

D Lacaille

http://www.w3.org/2001/XMLSchema#string

F Wolfe

http://www.w3.org/2001/XMLSchema#string

J Askling

http://www.w3.org/2001/XMLSchema#string

J Franklin

http://www.w3.org/2001/XMLSchema#string

K Qi

http://www.w3.org/2001/XMLSchema#string

M C Hochberg

http://www.w3.org/2001/XMLSchema#string

S Suissa

http://www.w3.org/2001/XMLSchema#string

T A Simon

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis

Meta-analysis in clinical trials

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Swedish registers to examine drug safety and clinical issues in RA.

P304

1819-1826

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2008.097527

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23569766

http://www.w3.org/2001/XMLSchema#string

P698

19054822

http://www.w3.org/2001/XMLSchema#string

P921

P932

2770103

http://www.w3.org/2001/XMLSchema#string